{"id":"gsk-biologicals-hiberix","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Injection site swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"}]},"_chembl":{"chemblId":"CHEMBL4303308","moleculeType":"Small molecule","molecularWeight":"389.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified polyribosylribitol phosphate (PRP) polysaccharide from the Hib capsule conjugated to meningococcal outer membrane protein complex (OMPC). This conjugation enhances immunogenicity by converting the T-cell-independent polysaccharide antigen into a T-cell-dependent response, resulting in stronger and more durable antibody production and immunological memory against Hib infection.","oneSentence":"Hiberix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:35.719Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive Haemophilus influenzae type b disease in infants and children"}]},"trialDetails":[{"nctId":"NCT00454987","phase":"PHASE4","title":"Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-16","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis, Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine","enrollment":288},{"nctId":"NCT01309646","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-04","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":454},{"nctId":"NCT01340898","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-27","conditions":"Meningococcal Infection","enrollment":753},{"nctId":"NCT01098474","phase":"PHASE2","title":"Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-07","conditions":"Tuberculosis","enrollment":301},{"nctId":"NCT01777308","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-03","conditions":"Infections, Meningococcal","enrollment":156},{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT00344318","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-07","conditions":"Infections, Streptococcal","enrollment":806},{"nctId":"NCT00911144","phase":"PHASE3","title":"Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-11","conditions":"Infections, Streptococcal","enrollment":450},{"nctId":"NCT00129129","phase":"PHASE2","title":"Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-08-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":756},{"nctId":"NCT00326118","phase":"PHASE3","title":"Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":433},{"nctId":"NCT00197236","phase":"PHASE3","title":"Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11-11","conditions":"Hepatitis A","enrollment":468},{"nctId":"NCT00436007","phase":"PHASE2","title":"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-30","conditions":"Malaria","enrollment":511},{"nctId":"NCT00317135","phase":"PHASE3","title":"Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12-11","conditions":"Diphtheria, Hepatitis B, Whole Cell Pertussis","enrollment":500},{"nctId":"NCT00317187","phase":"PHASE3","title":"Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06-08","conditions":"Hepatitis B, Diphtheria, Whole Cell Pertussis","enrollment":500},{"nctId":"NCT01000974","phase":"PHASE3","title":"Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-18","conditions":"Haemophilus Influenzae Type b","enrollment":4003},{"nctId":"NCT00680914","phase":"PHASE3","title":"Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-10","conditions":"Infections, Streptococcal","enrollment":503},{"nctId":"NCT00696423","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-07","conditions":"Acellular Pertussis, Diphtheria, Tetanus","enrollment":467},{"nctId":"NCT00291343","phase":"PHASE3","title":"Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-01","conditions":"Infections, Meningococcal","enrollment":296},{"nctId":"NCT00169442","phase":"PHASE3","title":"Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02-10","conditions":"Whole Cell Pertussis, Diphtheria, Hepatitis B","enrollment":745},{"nctId":"NCT00412854","phase":"PHASE3","title":"Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-03","conditions":"Tetanus, Diphtheria, Acellular Pertussis","enrollment":660},{"nctId":"NCT00473668","phase":"PHASE3","title":"Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-01","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Tetanus","enrollment":300},{"nctId":"NCT00323622","phase":"PHASE2","title":"Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Malaria","enrollment":1737},{"nctId":"NCT00197275","phase":"PHASE3","title":"Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02","conditions":"Tetanus, Hepatitis B, Haemophilus Influenzae Type b","enrollment":800},{"nctId":"NCT00332566","phase":"PHASE3","title":"Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06","conditions":"Hepatitis B, Whole Cell Pertussis, Tetanus","enrollment":148},{"nctId":"NCT00317122","phase":"PHASE3","title":"Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Diphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell Pertussis","enrollment":192},{"nctId":"NCT00290303","phase":"PHASE3","title":"Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05","conditions":"Haemophilus Influenzae Type b, Diphtheria, Whole Cell Pertussis","enrollment":996},{"nctId":"NCT01061541","phase":"PHASE2","title":"Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-08","conditions":"Haemophilus Influenzae Type b","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hib"],"phase":"phase_3","status":"active","brandName":"GSK Biologicals' Hiberix™","genericName":"GSK Biologicals' Hiberix™","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Hiberix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier. Used for Prevention of invasive Haemophilus influenzae type b disease in infants and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}